Sep
02

Treating T3 Deficiency (Part 6) Why T4 Thyroxine Therapy does not Improve Symptoms and Why TSH Suppression does NOT Result in Harm

Why T4 Thyroxine Therapy does not Improve Symptoms and Why TSH Suppression does NOT Result in Harm by Neal Rouzier, MD On Day 1 of the Part I BHRT Workshop Series, I introduced the concept that “Association Does Not Prove Causation (ADNPC).” Every course subsequent to Part I, I have to reintroduce the concept as
DETAIL
Feb
08

High Dose Replacement and Thyroid Optimization

The previous course on thyroid optimization was intended to contrast and explain how and why the endocrine societies and the ATA frighten us into not using thyroid hormone. I introduced the concepts that the endocrinologists use when treating hypothyroid patients as well as their reluctance to prescribe thyroid hormone to SC hypothyroid patients. Despite the plethora of data and studies proving that patients DON’T improve on T4-alone therapy, the ATA and AACE reject all the studies demonstrating that patients DO benefit when T3 is added to T4, but also when DTE is used preferentially in place of T4-alone or T4 and low dose T3. When used correctly, most recent literature overwhelming proves that patients prefer DTE over any other thyroid preparation.

DETAIL
Jan
11

A Review of the Studies on TSH Suppression

The last medical journal article that was presented in the last course, Treating T3 Deficiency: The Evidence You Need (Part 6), stated that exogenous hyperthyroidism (TSH suppression) with thyroid hormone administration was not associated (causative) of any adverse effect. “There is no scientific evidence that the clinical impact of TSH suppression is significant.” This meta-analysis proving no harm with thyroid hormone administration (along with TSH suppression) is in direct contrast to the opinions of the other papers/authors opinions reviewed in the last course. I reviewed many papers and opinions that TSH suppression was harmful. However, I emphasized that the studies cited were all studies that reviewed baseline TSH levels in patients with Graves’ disease. Not one study was an outcome study in patients that were prescribed/treated with thyroid hormone. However, the results of all these baseline observation studies demonstrated/proved that suppressed TSH levels (in Graves’ patients) were associated with harm, sudden cardiac death, a-fib, osteoporosis, etc. The authors of the various opinion papers went on to extrapolate that thyroid hormone administration resulting in suppressed TSH levels (biochemical hyperthyroidism) was just as bad/harmful as that seen in those studies citied in patients with Graves’ disease. Nothing could be further from the truth. That which is observed in treatment trials can be completely the opposite of what is observed in baseline observation studies. Another perfect example of ODNPC.

By Deirdre Nitsche | Blog . HRT Evidence Based Literature . Thyroid
DETAIL
Aug
06

Recent Literature Supports That Low Free T3 was the Highest Independent Predictor of Death in CV Patients

Recent Literature Supports That Low Free T3 was the Highest Independent Predictor of Death in CV Patients Written by Neal Rouzier, MD Recommended Pre-Reading: More Proof and Reasoning that T4 Monotherapy Results in Inadequate Conversion Treatment Scenario A 59 y/o female with CVD is referred by her friend for evaluation of hypothyroidism. Laboratory tests consistently
DETAIL
Jul
29

More Proof and Reasoning that T4 Monotherapy Results in Inadequate Conversion

More Proof and Reasoning that T4 Monotherapy Results in Inadequate Conversion Written by Neal Rouzier, MD Recommended Pre-Reading: If T4 Does not Improve Symptoms, and Normalizing TSH Does not Guarantee or Infer Improvement in Symptoms, Then How Should we Treat Patients? Treatment Scenario A 45 y/o female with persistent symptoms of fatigue, low energy, depression,
DETAIL
Jul
27

If T4 Does not Improve Symptoms, and Normalizing TSH Does not Guarantee or Infer Improvement in Symptoms, Then How Should we Treat Patients?

If T4 Does not Improve Symptoms, and Normalizing TSH Does not Guarantee or Infer Improvement in Symptoms, Then How Should we Treat Patients? Written by Neal Rouzier, MD Recommended Pre-Reading: Treating T3 Deficiency: The Evidence You Need Treatment Scenario Your 41 y/o PCOS patient that is optimized on thyroid returns with concerns that her PMD
DETAIL
Apr
08

Treating T3 Deficiency, the Evidence You Need

I do not believe that there is any one subject in medicine that is as misunderstood, politicized, debated, denigrated, and contentious as thyroid hormone. The pharmaceutical thyroid industry has spent millions on brain-washing physicians and convincing them that thyroxine is the best and only thyroid medicine that should be utilized. So many patients have relayed to me that their PMD will no longer treat them if they continue to take Armour Thyroid. 

DETAIL
Jul
21

The 7 Hormones Everyone Should Know

An overview of DHEA, Melatonin, Pregnenolone, Thyroid, Testosterone, Estrogen, and Progesterone

DETAIL